Piper Jaffray Companies set a $29.00 price objective on Bausch Health Companies (NYSE:BHC) in a research note released on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the company. ValuEngine raised Bausch Health Companies from a sell rating to a hold rating in a research report on Wednesday, May 8th. Zacks Investment Research raised Bausch Health Companies from a hold rating to a buy rating and set a $27.00 price target on the stock in a research report on Tuesday, May 21st. Cantor Fitzgerald set a $32.00 price target on Bausch Health Companies and gave the stock a buy rating in a research report on Friday, May 31st. Barclays began coverage on Bausch Health Companies in a research report on Tuesday. They set an overweight rating and a $28.00 price target on the stock. Finally, Wells Fargo & Co set a $9.00 price target on Bausch Health Companies and gave the stock a sell rating in a research report on Friday, May 17th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have given a buy rating to the stock. Bausch Health Companies currently has an average rating of Hold and a consensus target price of $27.65.

Shares of BHC stock opened at $22.13 on Tuesday. The firm has a market cap of $7.63 billion, a PE ratio of 5.50, a price-to-earnings-growth ratio of 0.48 and a beta of 0.61. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. Bausch Health Companies has a 12-month low of $17.20 and a 12-month high of $28.45.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Monday, May 6th. The company reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.14. The business had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The business’s quarterly revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share. On average, analysts predict that Bausch Health Companies will post 4.15 earnings per share for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Orbimed Advisors LLC boosted its holdings in Bausch Health Companies by 89.1% in the fourth quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock valued at $66,498,000 after purchasing an additional 1,696,400 shares during the last quarter. Financial Sense Advisors Inc. boosted its holdings in Bausch Health Companies by 7.7% in the fourth quarter. Financial Sense Advisors Inc. now owns 84,250 shares of the company’s stock valued at $1,556,000 after purchasing an additional 6,050 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Bausch Health Companies by 14.6% in the fourth quarter. Bank of Nova Scotia now owns 1,207,147 shares of the company’s stock valued at $22,296,000 after purchasing an additional 154,143 shares during the last quarter. Bessemer Group Inc. purchased a new stake in shares of Bausch Health Companies during the 4th quarter worth about $33,000. Finally, Highstreet Asset Management Inc. purchased a new stake in shares of Bausch Health Companies during the 1st quarter worth about $354,000. 53.67% of the stock is currently owned by hedge funds and other institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Further Reading: Trading Strategy Methods and Types

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.